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Background and objectives 
Etiological factors and accurate diagnostic biomarkers have remained elusive to pancreatic 
cancer, a disease with > 90% five-years mortality rate. The recent understanding of microbiome 
interaction with host organs has opened new research avenues on the potential role of 
microbiota in the tumor microenvironment. The objectives in Study I and II aim to investigate 
molecular and microbiome related biomarkers in plasma, saliva, pancreatic fluid and tissues 
from patient groups diagnosed with pancreatic cystic neoplasms, and their correlation with 
pancreatic neoplastic grade. 
The COVID-19 outbreak occurred in an unprecedented transmission rate which necessitate 
diagnostic biomarkers to manage the pandemic.  The objective in Study III aims to investigate 
the potential use of saliva as a non-invasive approach for assessment of immune exposure to 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 
Results 
Study I shows that elevated bacterial 16S DNA copies and IL-1β levels in pancreas cysts 
correlate with high neoplastic grade. Analysis of the intracystic pancreas microbiome shows 
co-occurrence and enrichment of oral bacterial species. Bacteria DNA level in pancreas is also 
associated to prior exposure to invasive endoscopic procedures. 
Study II shows that elevated plasma and salivary antibody reactivity to oral pathogens 
(particularly F. nucleatum or Fap2 of F. nucleatum) is associated with intraductal papillary 
mucinous neoplasm (IPMN) diagnosis showing high-grade dysplasia or invasive cancer.  
Study III shows that salivary antibody reactivity to SARS-CoV-2 spike and capsid antigens 
persist up to 9 months after mild COVID-19 with a new multiplex antibody assay. Presence of 
specific salivary antibodies also correlates to COVID-19 like symptoms in a second 
undiagnosed cohort. The virus-specific IgG in saliva appears stable and tolerates temperature 
and detergent pre-treatments. 
Conclusion 
Collectively, the results indicate that oral microbes have a role in disease progression of 
pancreatic cystic neoplasms. Reducing the inflammatory microbiome may be a potential 
therapeutic strategy. The salivary antibody testing against oral pathogens holds interesting 
promise for early identification of high-risk pancreatic tumors.  Furthermore, salivary antibody 
testings on a multiplex platform perform well and can support immune diagnostics of COVID-
19. By combining at-home sample collection and the multiplex strategy, salivary diagnostics 
can be a sensitive and non-invasive alternative to conventional tests currently available. 
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1.1   Pancreatic cancer 
1.1.1   Global incidence and mortality 
Pancreatic cancer (PC) is highly lethal, with the incidence rate closely matching the mortality 
rate 1. It is the fourth leading cause of cancer mortality in the United States  1. In Sweden, it is 
estimated that over 1400 patients died of pancreatic cancer in 2017 2, and approximately 
330,400 people die of PC each year worldwide 3.  The yearly incidence rates of PC are on the 
rise, and it is expected to be the second cause of cancer mortality before 2030 1,4. Up to 91% of 
PC patients die within five years of diagnosis, and more than 50% of them die in the first six 
months after the diagnosis 1,5,6. A substantial reason behind the high lethality of PC may be due 
to the lack of apparent symptoms and accurate diagnostic methods to detect the cancer, 
especially at an early stage, which results in mostly diagnosing PC in an advanced stage 7. 
Consequently, patients with late-stage PC were reported to have a high recurrence rate even 
after potentially curative resection of the pancreas 1. Biological characteristics and 
heterogeneity of the pancreatic tumor cells have contributed to PC´s resistance to radiotherapy 
and chemotherapy 8. Postmortem examinations showed that about 90% of PC cases were 
compromised by distant invasion and metastasis 9. 
Several risk factors are associated with increased risk of pancreatic cancer, such as cigarette 
smoking 10, obesity 11, diabetes mellitus 12, chronic pancreatitis 13, family history of pancreatic 
cancer 14, as well as periodontal disease 15.  Pancreatic cancer is an aging-associated disease 
that develops mostly in adults between 60 and 80 years old 1,5 with a 1.5 fold higher incidence 
rate in men than in women 5. Yet, there is no standard screening program for patients at high 
risk nor a clinically significant biomarker for PC.  Early detection of PC is an instrumental step 
to reduce PC mortality rate. Much remains to be explored about the pathogenesis, progression, 
diagnostic and therapeutic approaches for this cancer. 
The pancreas consists of both an exocrine and an endocrine part. The exocrine component 
contributes to the digestion of proteins, fats, and carbohydrates, thereby enabling absorption; 
the pancreas's endocrine component produces and secretes different hormones such as insulin 
and glucagon. Pancreatic cancer mainly develops in the exocrine duct and originates from the 
epithelial cellular lining of pancreatic ducts. Pancreatic ductal adenocarcinoma (PDAC) is the 
most common form of malignant pancreatic tumors, and it is thought to arise from benign 
precursor lesions that are classified under pancreatic cystic neoplasms (PCN) 16.   
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1.1.2   Precursors to pancreatic cancer 
1.1.2.1   Pancreatic cystic neoplasm (PCN) 
Pancreatic cystic neoplasms (PCN) have become an increasingly common clinical finding as 
the cross-sectional imaging diagnostic modalities are becoming more sensitive 17–19. Estimates 
from several studies show that the prevalence can be as high as 40% in the general population 
18,20,21. There are over 30 entities of cystic lesions in the pancreas known today, Kloppel and 
colleagues 22 have classified these into four groups. These groups are classified by the cystic 
lesion biology and morphology as: neoplastic epithelial, neoplastic non-epithelial, non-
neoplastic epithelial, and non-neoplastic non-epithelial cystic lesions. Examples of 
common/uncommon PCNs are shown in Figure 1. The neoplastic epithelial lesions constitute 
around 90% of PCN 23 and include the intraductal papillary mucinous neoplasm (IPMN), 
mucinous cyst neoplasms (MCNs), serous cystadenomas (SCA), and others. These three major 
subgroups (IPMN, MCN, and SCA) represent about 85% of all PCN, of which IPMN 





Fig. 1. Classification of pancreatic cyst neoplasms (Adapted from Chandwani, R et 
al,. 2016 24) 
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1.1.2.2   Intraductal papillary mucinous neoplasm (IPMN) 
One of the most common PCNs is the intraductal papillary mucinous neoplasm (IPMN) 23,27. 
IPMN is epithelial neoplastic cyst in the pancreas's ductal systems distinguished by the 
papillary projection of proliferated epithelial cells and mucin secretion that leads to dilated 
pancreatic duct 28. IPMN can arise in the main and side branches of pancreatic ducts, in the 
head, body, and tails of the pancreas 23. They may be localized, diffused, or multifocal 
distributed in the pancreatic ducts 23. 
IPMNs are known by their association with pancreatic malignancies, and it is believed that the 
dysplastic pattern of IPMN can progress from low-grade dysplasia (LGD) to high-grade 
dysplasia (HGD) and then transform to invasive carcinoma 27,29,30. The growing incidence of 
IPMN and its clear tendency to progress to invasive cancer led to great attention and efforts to 
detect it in its benign stage (LGD), which fortunately constitute most cases and does not require 
surgical intervention 17,23,28. Preoperative diagnostic accuracy is still not entirely reliable, and 
the guidelines of whether to resect the pancreas surgically as a prophylactic procedure or follow 
up the case conservatively are still debated 17. Thus, the surgical resection and routine follow-
up are indicated for most IPMNs patients as the final diagnosis can only be obtained 
histologically after operation 17,28. 
1.1.2.3   Mucinous cyst neoplasm (MCN) 
MCNs are notably less frequent than IPMNs, with a majority of the incidence occurring in 
women 23. In two extensive studies, the average of patients' age at diagnosis was 45 and 48 
years, with a predominant incidence in women in 95% of the cases 31,32.  As with IPMNs, 
MCNs produce mucin within the cysts and are classified according to the degree of dysplasia 
of the epithelial lining into low-grade dysplasia and high-grade dysplasia. MCNs also can 
potentially develop invasive carcinoma, which is shown histologically in about a third of 
surgically resected cases 33,34. MCNs can be histologically distinguished from IPMN and SCA 
by ovarian-like stroma underlying the epithelial layer 32. 
1.1.2.4   Serous cyst adenoma (SCA)   
SCAs are benign microcysts, which are characterized histologically by their cuboidal 
epithelium and thick walls 24. The fluid within the cyst is clear and thin and featured by the 
absence of carcinoembryonic antigen (CEA), a marker found to be elevated in mucinous cysts 
(e.g., IPMN and MCN) 35,36. SCA constitutes approximately 16% of all PCNs, and they possess 
very diminished malignancy transformation risk or invasive behaviour 37. Thus, surgical 
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intervention is not recommended, as the risk of mortality of pancreatic resection (2%) exceeds 
the risk of malignant transformation (>1%) 17,38. 
1.1.3   Oral bacteria and pancreatic cancer  
Several studies over the past decades suggested that microbiota play oncogenic roles and 
influence therapeutic responses in different tumours 39–43. In a recent study by Pushalkar et al., 
the increased relative abundance of bacteria in the pancreas and microbial dysbiosis in the gut 
were found to promote pancreatic tumorigenesis and induce immune suppression both in mice 
and humans 44.  
Distinct strains of oral commensal bacteria were found to be associated with distal tumor 
microenvironments in colorectal cancer 45,46. Table 1 presents several epidemiological studies 
that have investigated the association between oral microbiota and pancreatic cancer. In a study 
conducted in 2017, oral microbial dysbiosis was noted to occur prior to the development of 
pancreatic cancer 47. Furthermore, the link between pancreatic cancer and a history of 
periodontal disease or periodontal disease pathogens has also been reported in case-controlled 
studies 15,48–50. Consistent with these observations, periodontal disease pathogens and an 
increased level of plasma antibodies against distinct oral pathogens were related to an increased 
risk of pancreatic cancer 49,50. Fan, X. et al., reported in a large American study that the relative 
abundance of Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans in 
saliva was positively associated with the risk of PC. In contrast, the salivary richness in phylum 
Fusobacteria and its genus Leptotrichia appeared to decrease the risk of developing PC 50. The 
latter was found at the phylum and genus level without information shown at the species or 
strain level. 
1.1.4   Fusobacterium nucleatum and cancer immunity 
Despite the vast global microbial diversity, most microbiological studies have focused for 
decades on a few important taxa because of the challenges in cultivation and the high cost of 
genetic sequencing. This limited information makes the unstudied taxa all the more important 
51. Advanced sequencing techniques, such as metagenomics, revealed a vast diversity of 
microorganisms and helped to better understand many of these understudied microbes and their 
contribution to human diseases 52. Among them,  Fusobacteria phylum remains a prime 









Comparison, Sample size Outcome 
Farrell et al.,  
2012 53 
USA Saliva, 
16S gene qPCR 
Pancreatic cancer (n= 38) 
Chronic pancreatitis (n= 
27) 
Healthy control (n= 38) 
 
Significant variation of salivary microbiota between pancreatic 
cancer and healthy controls. 
G. adiacens and Streptococcus mitis showed significant variation 
between chronic pancreatitis and controls 
Michaud et al., 
2013 49 
Europe Blood antibodies, 
immunoblot array 
Pancreatic cancer (n= 405) 
Healthy control (n= 416) 
 
High antibodies level against Porphyromonas gingivalis 
associated with increased PC risk 
Torres et al.,  
2015 54 
USA Saliva, 
16S rRNA gene 
sequencing (V3-
V4) 
Pancreatic cancer (n= 8) 
Non-pancreatic 
disease/cancer (n= 78) 
Healthy control (n= 22) 
 
 
Higher ratio of Leptotrichia to Porphyromonas in pancreatic 
cancer compared to healthy and non-pancreatic diseases groups 
Fan et al., 
2016 50 
USA Oral wash, 
16S rRNA gene 
sequencing (V3-
V4) 
Pancreatic cancer (n= 361) 
Healthy controls (n= 317) 
Relative abundance of P. gingivalis and Aggregatibacter 
actinomycetemcomitans was associated with high risk of PC. 
Fusobacteria and its genus Leptotrichia appeared to decrease the 
risk of developing PC. 
Olson et al.,  
2017 55 
USA Saliva, 
16S rRNA gene 
sequencing (V4-
V5) 
Pancreatic cancer (n= 40) 
IPMN (n= 39) 
Healthy controls (n= 58) 
No significant difference in microbial diversity between PC and 
IPMN or controls. 
Higher relative proportions of Firmicutes in PC, and 
Proteobacteria in healthy controls 
Wei et al.,  
2020 56 
China Saliva, 
16S rRNA gene 
sequencing (V3-
V4) 
Pancreatic cancer (n= 41) 
Healthy controls (n= 69) 
Carriage of Streptococcus and Leptotrichia was associated with a 
higher risk of PC 




Fusobacteria phylum is currently classified into two families: the Fusobacteriaceae family and the 
Leptotrichiaceae family 52. They are anaerobic, rod-shaped bacteria with unique metabolic capabilities; 
for example, Psychrilyobacter atlanticus possess metabolic capability that can break down nitramine 
explosives 57.  
Fusobacterium nucleatum (F. nucleatum) is an emerging pathogen species under the Fusobacteriaceae 
family, and one of the most abundant bacteria in the oral cavity 58–60. F. nucleatum is a highly 
heterogeneous species with four recognized subspecies; ss nucleatum, ss animalis, ss vincentii 
(fusiforme) and ss polymorphum. Among those four subspecies, ss nucleatum appears more frequently 
associated with disease 61,62. F. nucleatum is non-motile, gram-negative, opportunistic oral anaerobe 
and known to play an integral part in biofilm formation of dental plaque 63,64. With its unique elongated 
rod shape and multifunctional cell membranes proteins, F. nucleatum can adhere and coaggregate with 
many other microbial cells and build infrastructure bridge between early and late colonizers to create 
multispecies colonies 63–65. However,  F. nucleatum is normally found in the mouth and other mucosal 
sites and it has been isolated from healthy tissues, indicating that they are a natural commensal member 
of oral microbiome 59,60,66,67. Under diseased conditions, F. nucleatum is referred to as an opportunistic 
pathogen as it has been frequently isolated from diseased tissues. In fact,  F. nucleatum is one of the 
most commonly isolated oral bacteria in oral and extra-oral diseases 68–71. This association of F. 
nucleatum with many extra-oral diseases is accumulative, but the pathogenesis remains unclear 71.   
F. nucleatum is gaining attention from the scientific community recently due to its over-representation 
in many cancer types, such as oral, gastric, colon and pancreatic tumors  45,46,72–75. Although F. 
nucleatum´s etiopathological role remains unclear, several studies identified specific proteins as the 
driving virulence factors in the pathogenesis and tumorigenesis of F. nucleatum in colorectal cancer 76–
78. F. nucleatum Fap2 protein plays a critical immunomodulating role by binding to TIGIT receptors 
and inhibiting NK cell cytotoxicity and other T cells 77. The FadA is another active virulence factor that 
has been identified as a mediator for F. nucleatum adhesion and invasion through binding to E‐cadherin 
and activation of the β‐catenin signaling pathway, leading to elevated expression of inflammatory and 
proliferation factors in epithelia cells, which promotes colorectal carcinogenesis (Figure 2) 78. 
Consequently, further studies are needed to investigate the role of oral bacteria in IPMN and the immune 
responses against these bacteria, which may provide a potential opportunity for early diagnostic 















1.2   COVID-19 
1.2.1   Global incidence and mortality  
In the 21st century, three emerging strains of the diverse coronaviruses group outbroke in humans from 
assumed zoonotic origin, causing mild to severe respiratory infections. The first outbreak was in 2002 
with severe acute respiratory syndrome coronavirus (SARS- CoV), the second was in 2012 with the 
Middle East respiratory syndrome coronavirus (MERS- CoV), and the third was in 2019 with severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2 ), which is the cause of coronavirus disease 
2019 (COVID-19) 79.  
The SARS-CoV-2 outbreak occurred in an unprecedented transmission rate since it was first reported 
in Wuhan, China in late December 2019  80 and was declared a pandemic by WHO on 11 March 2020 
81. As of April 2021, COVID-19´s global morbidity reached over 128 million confirmed cases and a 
mortality of up to 2.8 million from all six continents 82. 
1.2.2   SARS-CoV-2 infection and transmission 
Fig. 2. An overview of F. nucleatum virulence mechanisms. Fap2: fusobacterium 
autotransporter protein 2; FadA: Fusobacterium adhesin A; TIGIT: T‐cell immunoglobulin and 
ITIM domain; CEACAM1: carcinoembryonic antigen-related cell adhesion molecules 1; Gal‐
GalNAc: D‐galactose‐β (1–3)‐N‐acetyl‐D‐galactosamine; NK: natural killer; CRC: Colorectal 
cancer (REF 76-78). 
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Although genetic analysis showed that SARS-CoV-2  is a natural virus of animal origin and clustered 
with betacoronavirus found in bats and pangolin 83,84, there is no solid evidence yet about the 
intermediate host and when and where this novel virus transmitted to humans. As in SARS-CoV and 
MERS-CoV, SARS-CoV-2 targets the angiotensin-converting enzyme 2 (ACE2) receptor and utilizes 
it to enter host cells 85–87. The virus envelope spike (S) glycoprotein mediates SARS-CoV-2 entry into 
cells and is divided into two functional proteins: S1 protein (which includes the receptor-binding 
domain (RBD) mediates the binding to ACE2 receptor and S2 protein mediate the adhesion of SARS- 
CoV-2 to host cell membrane as shown in Figure 3 86,88. Biochemical analysis found that the spike 
protein of SARS-CoV-2 evolved and gained a higher binding affinity from its previous ancestor SARS-
CoV, which can explain the higher transmission ability of this later virus 89,90. However, another study 
reported a similar binding affinity of SARS-CoV-2  compared to the previous SARS- CoV 91. The oro-
nasal route is considered the main entry gates for SARS-CoV-2, and the ACE2 receptors have also been 
found to be highly expressed in the mucosa of nasal, pulmonary, as well as oral epithelial cells 92–95.  
 
 
Fig. 3. Schematic overview of SARS-CoV-2 spherical structure showing the S-trimer protein in 
pre-fusion conformation and N-protein (complexed with the viral RNA genome). TMPRSS2 
prime the S-protein to allow virus-cell fusion and cell entry. The S1 protein contains the RBD 
protein, which mediates binding to the ACE2 host cellular receptor. SARS-CoV-2: severe acute 
respiratory syndrome coronavirus 2; S-Protein: spike protein: N-Protein: nucleocapsid protein; 
RBD: receptor-binding domain; ACE2: angiotensin-converting; TMPRSS2: transmembrane 
serine protease 2 (adapted from REF 86-89). 
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1.2.3   Oral manifestations in COVID-19 
The SARS-CoV-2 transmission can occur through the oral cavity, and ACE2 receptors are expressed 
in the mucosal of oral epithelial cells 94,95. Recently, Huang et al. reported that even acellular and cellular 
salivary fractions from asymptomatic individuals may transmit SARS-CoV-2 ex vivo 95. This finding 
proposes a potential infection-related inflammatory response in the oral cavity organs and tissues, such 
as the salivary glands, tongue, and other oral sensory nerve endings. In fact, quantitative and qualitative 
impairment of taste bud sensitivity and dysfunctional gustatory responses are unique primary symptoms 
of SARS-CoV-2 infection, and is reported in 60% of patients with COVID-19. This impairment of taste 
bud sensitivity and dysfunctional gustatory responses were not reported in SARS and MERS infections 
96–98. Other case report studies observed various oral signs and symptoms related to SARS-CoV-2 
infection, such as non-specific oral ulcerations, desquamative gingivitis, and fungal candidiasis 98–100. 
However, there is no clear evidence whether these oral manifestations are directly related to SARS-
CoV-2  infection or only as consequences of the compromised immune system or adverse reactions of 
pharmacotherapy 101.  
1.2.4   Mucosal immunity to SARS-CoV-2   
Mucosal immunity forms the largest part of the entire immune system and refers to lymphocytes and 
antigen presenting cells in the epithelia of gastrointestinal and respiratory tracts 102. Antigen-activated 
B-lymphocytes, called plasma cells, secrete the antibodies into the lumen of the respiratory or 
gastrointestinal tract 102. Antibodies bind to microbes and toxins to prevent them from infecting cells 
through several effector mechanisms such as neutralization of microbes and toxins, coating (opsonize) 
microbes and transporting them for phagocytosis, and activation of the complement system that 
promote phagocytosis and destruction of microbes 102. The predominant antibody isotype produced in 
mucosal tissues is IgA (SIgA), and because of the large surface area of the mucosal organs, SIgA 
constitutes approximately 2 out of 3 grams of total antibody produced daily by healthy individuals 103. 
SIgA is produced by plasma cells in the lamina propria and migrated through the epithelial layer to bind 
to and neutralizes microbes in the lumen of mucosal organs 104. 
In general, the first protective barrier against microbial invasion is the mucosal surface of the respiratory 
and digestive systems 105. As SARS-CoV-2  primarily infects the upper respiratory tract, mucosal 
immune responses are expected to be induced via nasopharynx-associated lymphoid tissues, which 
refers to the adenoids, tonsils, and lining epithelium in the nasopharynx area 102. Other possible mucosal 
inductive sites were also reported in the bronchial lymphoid tissue in children 106, lacrimal duct 102,  and  
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the oral cavity 107. Bronchial lymphoid tissue is an effective inductive site of mucosal and systemic 
immune responses. However, it is normally involuted in the lungs of healthy adults 106, which raises a 
very important question about their potential instrumental contribution in the reported resistance to 




1.3   Molecular signature and disease biomarker 
1.3.1   Biomarker definition 
Biomarker is not a concept that is exclusive to modern medicine. The need for biomarkers to diagnose 
illness and diseases has been recognized in the history of medicine for centuries. Before 400 BC, 
ancients physicians used body fluids to diagnose diseases. Urine that attract insects was used as a way 
to diagnose patients with boils 109. 
Empirical sophisticated diagnostic techniques have come a long way and installed biomarkers as an 
imperative cornerstone of the modern healthcare system. Biomarkers are a vital part of healthcare 
development, offering comprehensive application tools for disease diagnosis, prediction, and prognosis. 
The term of biomarker is defined at the joint leadership conference of the U.S. Food and Drug 
Administration (FDA) and the National Institutes of Health (NIH) 110 as “A defined characteristic that 
is measured as an indicator of normal biological processes, pathogenic processes, or biological 
responses to an exposure or intervention, including therapeutic interventions. Biomarkers may include 
molecular, histologic, radiographic, or physiologic characteristics. A biomarker is not a measure of how 
an individual feels, functions, or survives.” and categorized into  
• risk biomarker 
• diagnostic biomarker 
• monitoring biomarker 
• prognostic biomarker 
• predictive biomarker 
• pharmacodynamic/response biomarker 
• safety biomarker. 
There are many types of biomarkers. Molecular biomarkers (e.g., genes, proteins, metabolites), 
imaging-based biomarkers (e.g., magnetic resonance images (MRI), X-ray), and other measurable 
biomarkers such as body weight, temperature, and heart rate. Molecular biomarkers play an integral 
role in the diagnosis and therapy guidelines in the modern healthcare system and even more so with 
increasing advancement in laboratory technologies. 
1.3.2   Molecular biomarkers 
From nucleic acid to protein, molecular biomarkers have been routinely used to diagnose health 
conditions in the current healthcare system. The molecular biomarker is defined as the candidate 
biomarker for a disease that can be detected based on a platform such as genomics and proteomics 
technologies 111. Although the importance of molecular biomarkers has been increasingly recognized 
in recent years, their validation is a lengthy process, so that only a few biomarkers have so far been 
routinely used in clinical practice 112,113. As a general rule, the most sensitive and specific biomarker is 




1.3.3   Current biomarkers for pancreatic cystic neoplasms 
The absence of a predictive biomarker and validated screening program for patients at high risk of 
developing PC limited the ability for early detection of PC. However, there is emerging data on 
biomarkers in the past two decades with the advancement of cross-sectional imaging modalities and 
molecular diagnostic techniques. Identification of the cystic precursor to PC is of primary importance 
for preventive intervention that would improve the poor prognosis of PC. 
1.3.3.1   Imaging-based biomarkers 
The advancement in cross-sectional imaging provided tremendous help in the detection of pancreatic 
neoplasms. The most commonly used imaging modalities are computed tomography (CT) and magnetic 
resonance imaging (MRI). MRI is the preferred method for fellow-up of PCN 114. Endoscopic 
ultrasonography (EUS) is commonly employed as an adjunct diagnostic tool to improve the accuracy 
of the initial cross-sectional imaging diagnosis or to obtain a cyst fluid sample for cytology and 
biochemical analysis 17. Despite advancements in cross-sectional imaging, radiographic imaging is not 
yet able to provide a definitive diagnosis24 
1.3.3.2   Cystic fluid analysis 
To improve the diagnostic accuracy of PCNs, EUS with fine-needle aspiration is commonly indicated 
as an adjunctive procedure for cytopathological examination 17. Multiple markers have been studied, 
including the carcinoembryonic antigen (CEA) 115, carbohydrate antigen (CA) 19-9 115, K-ras, and 
amylase. For example, CEA level is used for the differentiation between mucinous and non-mucinous 
PCN 36, an increased level of CA 19-9 is associated with the increased risk of malignancy 17 and the 
presence of amylase in the cystic fluid is a sign to exclude pseudocyst (as it has no connection with 
pancreatic ducts) 116. However, these tumor markers suffer from low sensitivity and specificity and are 
not considered as screening tools for PC 117. Similarly, cytological studies based on cyst fluid also 
appeared unreliable as the fluid may have low cellularity and extracellular contamination 116.  
1.3.3.3   Cancer mutation 
Cancers are driven by an accumulation of activated oncogenes and tumor suppressors by mutations or 
overexpression. Several gene mutations have been implicated in pancreatic neoplastic cyst formation. 
These include KRAS, p53, GNAS and SMAD4 118. KRAS and GNAS mutations showed high 
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sensitivity in detecting IPMN in highly sensitive techniques, such as next-generation sequencing (NGS) 
119, yet appeared suboptimal in their specificity for differentiating invasive pancreatic tumors 120. 
1.3.4   Current biomarkers for COVID-19 
The use of COVID-19 biomarkers in the current pandemic state is not only important for pandemic 
management but also are necessary for developing therapeutics and preventive measures including 
vaccination. Detection and quantification of the virus or the virus-specific antibodies are presently 
standard analytical methods used in COVID-19 diagnostics. There are mainly PCR-based assays 121 or 
immunological assays 122,123. The current gold standard for COVID-19 diagnosis is real-time RT-PCR 
detection of SARS-CoV-2 RNA using samples taken from upper respiratory (naso-pharyngeal swab 
with or without saliva )121,124. Methods based on saliva specimens were found as a sensitive alternative 
for diagnosis of asymptomatic and mild SARS-CoV-2 infection 125,126. Other tests based on the 
detection of viral antigens also exist as rapid screening alternatives 127 and the available tests today are 
both laboratory-based or self-performed using lateral-flow devices. 
1.3.4.1   Biomarkers of COVID-19 severity 
Routine laboratory tests applied in clinical settings have been analyzed to assess their association with 
COVID-19 severity. Elevated concentrations of serum biomarkers such as urea, creatinine, cystatin C 
were associated with severe cases of SARS-CoV-2 infection 128. Inflammatory biomarkers such as C-
reactive protein, procalcitonin, IL-6 were also reported to be significantly increased in severely infected 
patients compared with non-severe cases 93,129. Critical risk factors that could be used as biomarkers for 
COVID-19 severity include the patient's age, as higher ACE2 density was found to be positively 
correlated with age 93. However, all of the previous findings were based on retrospective and cross-






2 RESEARCH AIMS 
2.1   General aim 
The general aims for studies I and II of this thesis were to investigate molecular and immunological 
biomarkers (in plasma, cyst fluid, pancreatic tissue, and saliva) in patients diagnosed with PCN, and 
the microbiome association with a particular interest in IPMN. 
The aim for Study III was to investigate the potential use of salivary antibodies as an immunological 
marker for exposure to SARS-CoV-2. 
2.2   Specific aims 
Study I 
To investigate pancreatic cyst fluid and plasma in patients diagnosed with PCN, with regard to potential 
pancreatic microbiome, inflammation, and their relation to disease severity. 
Study II 
To investigate humoral responses to oral microbes in the plasma and saliva of patients diagnosed with 
PCN, including response to F. nucleatum Fap2. 
Study III 
To investigate salivary antibody immunity against viral proteins of SARS-CoV-2 in individuals with 





3 MATERIALS AND METHODS 
3.1   Ethical considerations 
The studies performed here were approved by the Swedish Ethical Review Authority and complied 
with the declaration of Helsinki. All studies participants signed an informed consent form prior to study 
participation. 
3.2   Patients recruitment 
In study I, a total of 105 patients undergoing surgical pancreatectomy for suspicion of high-risk 
pancreatic cyst tumors were recruited from 2017-2019 at Karolinska University Hospital, Stockholm, 
Sweden.  In study II, a total of 109 plasma and 65 paired saliva samples (among them 8 saliva samples 
from healthy individuals) were collected from patients undergoing surgical pancreatectomy for 
suspicion of high-risk pancreatic cyst tumors were recruited from 2017-2019 at Karolinska University 
Hospital, Stockholm, Sweden. The patients in study I and II were stratified according to post-operative 
histopathological diagnosis into non-IPMN, LGD-IPMN, or HGD-IPMN and cancer. 
In study III, a total of 256 saliva samples were collected and stratified into three cohorts. Cohort 1: 
included 74 samples from convalescent COVID-19 patients collected from June to December 2020; 
cohort 2: included 147 samples from undiagnosed individuals who donated their saliva between May-
Nov 2020; cohort 3: included 35 pre-pandemic saliva samples collected from 2018 before the COVID-
19 outbreak. Samples in study III were collected from participants at Karolinska University Hospital, 
Dental Clinics of Karolinska Institutet and Eastman Institute, Stockholm, Sweden. 
3.3   Self-reported questionnaire and examination 
In study II, a self-reported questionnaire was used for all participants who donated saliva (n=57). This 
questionnaire was composed of eight closed-ended questions to assess the oral health condition. The 
questions were formulated based on the CDC-AAP case definitions for surveillance of periodontitis 130. 
Clinical dental health examination was performed for healthy participants (n= 8) without known PCN 
diagnosis to provide better control baseline data for subsequent analysis. The clinical dental 
examination was performed by recording full-mouth bleeding on probing (BOP), periodontal pocket 
depth (PPD), plaque index (PI) and number of missing teeth. 
In study III, self-reported questionnaire was used to collect COVID-19-related information from 
participants. Data related to potential exposures, including self-experienced symptoms in the past three 






3.4   Blood collection 
In study I and II, peripheral venous blood sample were collected in 10 ml K2 EDTA tubes (BD 
Vacutainer) and centrifuged for plasma (20 min at 2000 g at room temperature) in Ficoll Paque PLUS 
(GE Life Sciences) density gradient according to manufacturers’ instructions, then immediately stored 
at −80C. 
3.5   Saliva collection 
In study II, stimulated saliva was collected in the evening before pancreas surgery. The participants 
were asked to refrain from eating, drinking, smoking, or using oral hygiene products for at least 1 h 
prior to collection. Stimulated whole saliva was collected in sterile 50 mL polyethylene tubes and stored 
immediately stored at −80◦C in 1.5 mL aliquots. 
In study III, unstimulated saliva samples were self-collected in 2 ml tubes using standardized 
instructions given by this study, processed and stored at -80C within 24 h. 
3.6   Microbial DNA extraction 
Microbial DNA was isolated in study I from intracystic fluid and plasma; and in study II from bacterial 
culture or saliva using ZymoBIOMICSTM DNA Mini Kit (Zymo Research, Irvine, California, United 
States) according to the manufacturer’s instructions in a biological class II flow cabinet. In study I, 
DNA was also extracted from formalin-fixed paraffin-embedded (FFPE) pancreatic tissue slices using 
the AllPrep DNA/RNA FFPE Kit (Qiagen, Sollentuna, Sweden). All isolated DNA were stored at 
−20C until use. 
3.7   Sequencing and quantification of bacterial DNA 
In studies I and II, universal bacterial 16S DNA gene copy number was amplified by TaqMan qPCR 
using forward primer: 5’- TGGAGCATGTGGTTTAATTCGA-3, and reverse primer: 5’-TGC 
GGGACTTAACCCAACA-3’, as 16S probe was 5’-FAM- 
CACGAGCTGACGACA[A/G]CCATGCA-TAMRA-3’ 131. In study I, cyst fluid microbial 
composition and diversity was assessed by full-length 16S rRNA gene sequencing PacBio Single 
Molecule, (GATC Biotech, Konstanz, Germany). For gDNA quantification of F. nucleatum (studies I, 
II), and Granulicatella adiacens (G. adiacens) (study I), primers used for F. nucleatum 16S gene were: 
Forward 5’-AGGGTGAACGGCCACAAG-3’, Reverse: 5’-TCTCGGTCCATTGTCCAATATTCC-
3’ and probe 5’-FAM- ACACGGCCCTTACTCC -TAMRA-3’ 132,133. Primers for G. adiacens were: 
Forward 5’- CAAGCTTCTGCTGATGGATGGA-3’, Reverse 5’-CTC 
AGGTCGGCTATGCATCAC-3’, and 5’-FAM- GCTAGTTGGTGAGGTAACGGCTCA-TAMRA-





3.8   Bacterial cell isolation and inactivation methods 
In study II, microbial strains of Streptococcus gordonii (S. gordonii), Streptococcus anginosus (S. 
anginosus), G. adiacens, and Escherichia coli (E. coli) were isolated from pancreatic cyst fluid samples 
by cultivation and identified by matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS; Bruker Daltonik, Bremen, Germany) profiling (Study I), thereafter 
cultured on blood and hematin agar plates. F. nucleatum and P. gingivalis strains were isolated from 
clinical blood cultures, identified in standard clinical routine by MALDI-TOF MS, then cultured on 
blood agar in anaerobic milieu 48 h at 37C. The plates were examined after 24 h. Liquid cultures were 
prepared with glycerol (20% final concentration) prior to storage at −80C. For enzyme-linked 
immunosorbent assay (ELISA) analysis, the bacteria preparations were pre-treated by heat-inactivation. 
Briefly, the bacteria pelleted at 1 × 109 CFU were washed twice in PBS and heat-inactivated at 85C 
for 1 h. The F. nucleatum Fap2 (Fap2) mimotope TELAYKHYFGT as described earlier by prediction 
analysis (The Immune Epitope Database (IEDB) Analysis Resource) 134, was synthesized to 98% purity 
(Genscript, New York, United States). Of note, an ELISA optimization was first performed with either 
heat- or formalin-inactivated bacteria preparations of F. nucleatum (1 × 108 CFU/ml and 1 ×107 
CFU/ml) and plasma samples in serial dilutions at 1:300, 1:1500, 1:7500. The heat inactivation method 
using F. nucleatum concentration of 5 × 107 CFU/mL, and 1:300 plasma dilution were selected for the 
subsequent analysis. 
3.9   ELISA assays 
In study II, the heat-killed bacterial preparations were prepared for antibody analysis. The F. nucleatum 
and Fap2 mimotope were the antigens of interest. P. gingivalis, S. gordonii, S. anginosus, and G. 
adiacens were included as oral bacterial controls and E. coli as a non-oral bacterial control. Indicated 
bacteria were diluted to the concentrations of 5 × 107 CFU/mL and the mimotope at 10 µg/mL in coating 
buffer (sodium carbonate buffer 50 mM, pH 9.6). Thereafter, 100 µL of the antigen were added to each 
well of a Nunc MaxiSorpTM 96-well ELISA plate (Sigma-Aldrich Sweden AB, Stockholm, Sweden) 
for overnight incubation at 4C. The antigen-coated wells were washed three times with washing buffer 
(0.05% Tween-20 [VWR Chemicals, Spånga, Sweden] in PBS), and blocked by blocking/dilution 
buffer (1% BSA and 2% goat serum [Sigma-Aldrich, G6767] in PBS) and incubated for another 1 h at 
37C and washed before addition of sample diluents. Diluents of plasma (1:300) and saliva (1:16) 
respectively, were added in duplicate wells and incubated for 1 h at 37C. After washing, the wells were 
incubated with a secondary antibody the goat anti-human IgG/IgA conjugated with peroxidase diluted 
1:10000 (Sigma-Aldrich Sweden AB) for 1 h at 37C. Thereafter the substrate tetramethylbenzidine 
(R&D Systems, Minneapolis, Minnesota, United States) was added for 20 min and the reaction was 
stopped with the addition of 0.16 M sulfuric acid. The optical density was read at 450 nm (Multiskan 
MS, Thermo Labsystems, Vantaa, Finland). The total IgG and IgA detection was also performed, in 
which samples were diluted to 1:125 000 and 1:5000 for plasma and saliva, respectively, and detected 
as above as for specific antibodies. Internal controls consisting of high-reactive and low-reactive 
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patients’ plasma or saliva samples were included in each plate. The OD measurements of internal 
controls were used to calculate the inter/intra-assay coefficient of variability for all runs. Inter-assay 
coefficient of variability was 8.5 ± 4.5% and 10.4 ± 2.3%, respectively, for plasma and saliva assays, 
while the intra-assay coefficients of variability were 8 ± 2.3% and 8.7 ± 1%, respectively.  
The competitive ELISA assay was performed by first coating plates with Fap2 peptide overnight. On 
the following day, saliva samples with or without pre-incubation with F. nucleatum, Fap2, or the E. coli 
control (2 h at 37◦C) were added to the Fap2 peptide-coated plates and analyzed as above (Figure 4). 
Total salivary and plasma IgA and IgG antibodies were determined using Human IgA/IgG ELISA Kit 







3.10   Multiplex bead-based immunoassay 
In study III, salivary antibodies against SARS-CoV-2 were analyzed by a multiplex bead-based 
immunoassay (Figure 5). The assay was optimized first using a panel of five SARS-CoV-2 protein 
antigens: 1) spike trimers comprising the prefusion-stabilized spike glycoprotein ectodomain 
Fig. 4. Principle for the competitive ELISA used in this thesis. Pre-incubated saliva sample with 
indicated antigen was added to the Fap2-coated wells and allowed for Ag-Ab competition. When 
the pre-incubated antigen outcompetes the Fap2-coated antigen in binding to the salivary 
antibodies, the concentration of the salivary antibodies will be low after wash (A). When the 
Fap2-coated antigen outcompetes the pre-incubated antigen in binding to the salivary antibodies, 
the concentration of the bound salivary antibodies will be high after wash (B). Fap2: 
fusobacterium autotransporter protein 2; Ag: antigen; Ab: antibody; OD: optical density. 
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(expressed in human embryonic kidney (HEK) cells and purified using a C-terminal Strep II tag); 2) 
spike S1 domain (Sino Biological, expressed in HEK and purified using a C-terminal His-tag); 3) spike 
RBD domain (expressed in HEK cells and purified using the mFc C tag); 4) full -length nucleocapsid 
protein; 5) nucleocapsid C-terminal chain. Both nucleocapsid were expressed in E.coli and purified 
using a C-terminal His-tag 135,136. All antigens were diluted to 80 µg/ml (in 2-(N-morpholino) ethane 
sulfonic acid buffer, pH 4.5 [SigmaAldrich]) and coated on specific color-coded bead type (bead ID) 
(MagPlex-C, Luminex corp.). The antigen-suspended beads were pooled to form the bead array. Anti-
human IgG (309-005-082, Jackson Immunoresearch) and anti-human IgA (800-338-9579, Bethyl) 
labeled on the surface of microspheres, and the EBV EBNA1 protein (ab138345, Abcam) were added 
as a sample loading control. Saliva samples were diluted 1:5 in assay buffer (3% bovine serum albumin 
[w/v], 5% non-fat milk [w/v], 1×PBS supplemented with 0.05 % [v/v], and Tween20 [VWR, 
437082Q]) and incubated with the bead array for 1 h at room temperature and 650 RPM rotation. 
Afterward, the antigen-antibody complexes were cross-linked by adding 0.2% paraformaldehyde 
(AlfaAesar, 30525-89-4) in PBS 0.05% Tween 20 (PBS-T) for 10 min at room temperature. Salivary 
IgG or IgA that were captured on the antigen-coated beads were detected by the fluorescent R-
phycoerythrin-conjugated anti-human IgG (H10104, Invitrogen) diluted 0.4 µg/mL, or R-
phycoerythrin-conjugated anti-human IgA (800-338-9579, Bethyl) diluted 0.2 µg/mL in PBS-T, 
respectively, after 30 minutes incubation at room temperature. The read-out consisted of the bead-based 







Fig. 5. Illustration principle for the multiplex bead-based immunoassay used in this thesis. The 
saliva sample is added to a mixture of color-indexed beads pre-coated with indicated antigens (A) 
to form antigen-antibody complexes (B). The captured salivary antibody is detected by the 
secondary antibody conjugated to transmit a reporter fluorescent signal. The emitted light from 
the reporter signal is measured and the antigen specificity is determined by the color of the bead. 
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3.11   Statistical analysis 
Statistical analyses were mainly performed with GraphPad Prism (version 8.00 for Windows, GraphPad 
Software, La Jolla, CA, United States). In study I, pairwise statistical comparisons between each group 
were performed using Fisher’s exact test (for qualitative parameters), and Kruskal–Wallis test with 
Dunn’s multiple comparisons correction (for quantitative parameters). Non-parametric Kruskal-Wallis 
test with Dunn’s multiple comparison test were performed to determine the quantitative difference of 
bacterial 16S DNA copies, IL-1β or LPS between the diagnosed groups. Spearman's analysis was used 
to correlate 16S DNA and IL-1β quantities. Mann-Whitney unpaired non-parametric test were used to 
compare 16S DNA or IL-1β levels between IPMN LGD and IPMN HGD and also to compare the levels 
of 16S DNA or IL-1β in relation to previous endoscopic procedures or use of proton-pump inhibitors. 
To analyse bacterial compositional, Chao1 richness, Shannon diversity or inverted Simpson’s indices 
were analyzed and compared using Kruskal-Wallis test with Dunn’s test. Bar plots were shown also for 
bacterial relative abundance at phylum and genus levels. Beta diversity between samples visualised by 
cluster heatmap, PCoA spider plots and bacterial co-occurrence network. Linear discriminant analysis 
effect size was used to identify the relative abundant bacterial genera between the three diagnosed 
groups (IPMN LGD, IPMN HGD and cancer). 
In study II, for quantitative and qualitative parameters Kruskal–Wallis test with Dunn’s multiple 
comparisons and Fisher’s exact test were used, respectively. To analyse the difference in antibody 
responses between the diagnosed groups, Kolmogorov–Smirnov test was used. The correlation between 
plasma IgG and salivary IgA reactivity against F. nucleatum was examined with Pearson analysis. 
Pearson analysis was used to correlate plasma IgG and salivary IgA reactivity against F. nucleatum. 
Pairwise Wilcoxon test was used for competitive ELISA. The ELISA cut-off values were computed 
based on the formula described by Frey et al. on healthy controls 137, values above the cut-off were 
assigned as reactive while those that were lower as non-reactive. 
In study III, visualizations of the multiplex bead array data were performed using R (version 3.6.1) with 
RStudio (version1.2.1335) and the additional packages heatmap (1.0.10), reshape2 (1.4.3). GraphPad 
Prism Version 9.0.0 was used for the non-parametric comparisons Mann-Whitney test and Spearman 
correlation analysis. For comparisons of binomial datasets, N1 Chi-squared test was used. A cutoff for 
positivity was calculated per antigen as the mean + 6X SD of 12 negative pre-pandemic reference 
samples carefully selected based on their signal intensity distribution. Descriptive analyses were made 






4 RESULTS AND DISCUSSION 
4.1   Study I 
IPMN is a common type of PCN and has significant potential to malignant transformation. A better 
pre-operative identification of high risk IPMN patients will not only improve pancreatic cancer 
management but also reduce the burden of unnecessary surgical interventions and life-long follow-ups. 
4.1.1   Study population characteristics 
The clinical characteristics of all study subjects were grouped on diagnosis-basis and analyzed. In 
comparison, the cancer group is on average older than non-IPMN group and represented with higher 
serum concentrations of Ca 19-9, hemoglobin A1c, albumin, and bilirubin than non-IPMN. In general,  
Ca 19-9 is the only tumor biomarker approved by the Food and Drug Administration (FDA) and offers 
a sensitivity of 79% and specificity of 82% to detect tumor 138; but is not used to predict tumors in 
asymptomatic patients 139. There were more incidences of high levels of Ca 19-9 (>34 U/mL) in the 
cancer group (70.4%) compared to non-IPMN group (23.8%) in our study. 
4.1.2   Bacterial 16S DNA and IL-1β quantification 
Intracystic bacterial 16S DNA copies and IL-1β were found in this study to be associated with 
pancreatic cystic lesions severity. Compared to non-IPMN, higher bacterial 16S DNA copies and IL-
1β were found in IPMN (p=0.0042 and p=0.029, respectively) and cancer (p=0.0008, and p=0.0024, 
respectively). The elevated bacterial 16S DNA were also positively correlated with IL-1β levels. Post-
IPMN stratification into IPMN-LGD and IPMN-HGD showed higher IPMN-HGD intracystic bacterial 
16S DNA (p=0.02), and IL-1β (p=0.0032) compared to IPMN-LGD. This finding of elevated 
proinflammatory IL-1β agrees with other studies that reported IL-1β levels in the cyst fluid as a 
discriminative marker to predict IPMN dysplastic grade 140,141. The inflammatory mediator IL-1β is 
known to play a crucial role in cancer: promoting invasiveness, and metastasis via inflammation in the 
cancer microenvironment 142; alternatively, inflammation can be a result of ductal obstruction and 
release of damage-associated molecular pattern (DAMP) molecules. To investigate potential microbial 
involvement in this intracystic inflammatory response, bacterial 16S DNA and pathogen-specific 
molecules (LPS) were quantified in our study and correlated to IL-1β levels. The results of elevated 
cyst fluid IL-1β levels in high-risk IPMN group and their positive correlation with bacterial load and 
LPS levels suggest a local pancreatic microbiome role in the malignant progression of IPMN. 
4.1.3   Microbial compositional analysis 
To investigate bacterial composition in the IPMN cyst fluid and whether it is associated with disease 
progression, full-length bacterial 16S rRNA genes were measured using PacBio technology. This was 
performed on cyst fluid that passed quantity and quality control for content of 16S DNA. It was found 
that IPMN LGD (n=14) or IPMN HGD (n=8) and cancer (n=14) group revealed a highly diverse 
microbiome and showed no significant differences at operational taxonomic unit (OTU) level for Chao1 
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richness, Shannon diversity, or inverted Simpson's indices. At the phylum level, IPMN LGD was 
predominated by Proteobacteria, while IPMN HGD and cancer were either dominated by Firmicutes or 
Proteobacteria. At the genus level, the microbial composition was found to be heterogeneous with no 
distinctive profile according to the group diagnosis. 
4.1.4   Co-occurrence of oral pathogens in IPMN 
Visualization of bacterial species with network analysis revealed a co-occurrence of F. nucleatum with 
several other species, including Serratia marcescens, Parvimonas micra, Prevotella melaninogenica, 
Haemophilus parahaemolyticus, Streptococcus anginosus, Bergeyella sp. HMT322, Kluyvera 
ascorbata, Eikenella corrodens, Campylobacte concisus and Campylobacter showae, some of which 
appear to be members of the oral microbiome.  Other known oral members also showed high relative 
abundances, such as G. adiacens and S. anginosus. 
4.1.5   Relative abundant bacterial genera based on group diagnosis 
Result determined by LEfSe (Linear discriminant analysis Effect Size) that determines the features most 
likely to explain the differences between classes by coupling standard tests for statistical significance 
with additional tests encoding biological consistency and effect relevance 143 showed 15 relatively 
abundant bacterial genera in the three diagnosed IPMN groups. Among them, Granulicatella, Serratia, 
and Fusobacterium were found to be highly abundant in IPMN HGD compared to IPMN LGD and 
cancer. Subsequent validation analysis for F. nucleatum genome in IPMN cyst fluid and formalin-fixed 
tissue samples by a targeted qPCR assay showed increased F. nucleatum DNA copy number in the 
IPMN HGD and cancer group.  
The association of F. nucleatum in tumor tissue has been demonstrated previously in colorectal cancer, 
not only by PCR 73,144, but also via non-amplification-based techniques such as 16S ribosomal RNA 
(rRNA) fluorescent in situ hybridization (FISH) 145. The biology of tumor mechanisms - angiogenesis, 
permeability, immunosuppression, and the hypoxic condition may attract microbiome to inhabit the 
tumor microenvironment 146. Earlier studies indicate that F. nucleatum is an example of overrepresented 
microbiota in the tumor microenvironment with its anaerobic nature, and specific adhesion capabilities 
to Gal-GalNAc lectin expressed on the surface of host cells and many microbe cells 147. Abed and 
colleagues also demonstrated that F. nucleatum Fap2 protein can attach to tumor-overexpressed Gal-
GalNAc in colorectal cancer tissues in an experimental mouse model, suggesting that targeting Fap2 
may reduce F. nucleatum potentiation of cancer and offer diagnostic opportunity as well 76. 
4.1.6   Association of intracystic bacterial load and clinical parameters 
To investigate potential bacterial translocating factors, we correlated bacterial DNA quantity with 
routine clinical procedures. Prior invasive endoscopic procedures (IEP), use of proton-pump inhibitors 
(PPI) or antibiotics were examined. Our results showed an association between the intracystic bacterial 
quantity and the history of IEP (p=0.0017), which goes in line with another study that reported a higher 
bacterial amount in the pancreas of patients who required endoscopic biliary stenting to decompress 
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biliary obstruction compared with those who did not require the procedure 148. However, more IEP 
exposures did not increase the bacterial load, and the history of IEP was also not associated with the 
severity of IPMN. In fact, some IPMN HGD and cancer patients with no history of IEP were still having 
higher intracystic bacterial load than SCN group (p=0.0268), suggesting other bacterial translocation 
routes into the pancreas could exist. Furthermore, IL-1β or F. nucleatum increase was independent of 
the history of IEP and use of PPI. The routes of bacterial translocation are debated, but accesses via 
gastrointestinal tract, circulation, and lymphoid system have been proposed in the literature 149. As 
reported by Geller et al, although the presence of microbiota can be detected in 76% (86/113) of 
pancreatic cancer samples, it is also seen in 15% (3/20) of normal, non-pathologic pancreatic tissues150. 
Our result is interesting, giving a plausible scenario to the potential reflux phenomenon of bacteria from 
the duodenum to the pancreas, especially with the reported similarity of abundant bacteria in PC to 
bacterial flora of duodenum 151. Taken together, these findings suggest that the pancreas, a previously 
regarded sterile organ, may host microbiome niches, and the abundance of bacteria in pancreas may be 
a driver to chronic inflammation, generating an inflammatory microenvironment that may further 
promote tumor progression 152.   
 
4.2  Study II 
4.2.1   Characteristics of study subjects 
Plasma samples (n = 109) and saliva samples (n = 65) from patients undergoing pancreatic resection 
surgery and healthy controls were investigated. The samples were stratified into HGD-IPMN + cancer 
(n = 46), LGD-IPMN (n = 45), and non-IPMN (n = 18) based on the postoperative diagnosis confirmed 
by histopathology. In these cohorts, the non-IPMN participants were younger than IPMN groups and 
predominated by females, as they were mainly SCN patients. Diabetes was also found more common 
in the high-risk IPMN group (IPMN HGD and cancer), which is in agreement with a previous study 153. 
4.2.2   Plasma antibody responses to oral microbiota and high-risk IPMN 
This study's interest was to evaluate antibody reactivities to the enriched oral bacteria detected in study 
I. Plasma IgG binding antibodies showed stronger reactivity than IgA when tested against F. nucleatum, 
G. adiacens, S. gordonii, S. anginosus, E. coli and F. nucleatum Fap2 by indirect ELISA. High-risk 
IPMN (HGD-IPMN + cancer) group showed higher F. nucleatum (p<0.0006) and lower G. adiacens 
(p<0.002) antibody reactivities compared to non-IPMN group. To rule out potential IgG deficiency 
bias, total IgG levels were analyzed and showed comparable levels between all groups. 
4.2.3  Salivary antibody responses to oral microbiota and high-risk IPMN 
Our results showed that the HGD-IPMN + cancer group had higher IgA antibody reactivities to F. 
nucleatum, G. adiacens, and F. nucleatum Fap2 as compared to other groups (LGD-IPMN and control). 
Of note, the oral health periodontal data showed comparable oral health conditions across all groups. 
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The oral health data served to reduce the potential bias of periodontal disease involvement in the HGD-
IPMN + cancer group, as F. nucleatum is one of the principal periodontal pathogens 58,154. Since 
periodontitis is reported to be prevalent in adults 155, and the IPMN HGD + cancer group were shown 
in this cohort to be older in age than controls, correlation analysis between age and antibodies levels 
were performed to determine age as confounding factor. As shown in Figure 6, no significant 
correlations between age and IgG or IgA reactivities was found in both F. nucleatum and Fap2. 
However interestingly, salivary IgA reactivities to F. nucleatum Fap2 were shown to be positively 
correlated to F. nucleatum (r= 0.685, p<0.0001), which prompted us to validate salivary IgA bindings 




4.2.4  Confirming salivary IgA specificity to Fap2 mimotope 
To confirm the IgA specificity to Fap2, saliva samples pre-incubated with F. nucleatum or E. coli 
(control) and added to Fap2-coated wells in a competitive ELISA test. The binding was reduced with 
F. nucleatum pre-incubated samples by 24 ± 31% but not with the control E. coli (1.7 ± 25%). Our data 
also showed that IgA in saliva pre-incubated with Fap2 are also outcompeted for the binding to F. 
nucleatum whole cell (coating antigen), suggesting specific antagonist affinity to Fap2 (Figure 7). Our 
result adds to the current notions on host immune interaction with Fap2, which is considered as a 
virulence mechanism in the tumor microenvironment. Other Fap2´s virulence mechanisms include the 
inhibition of the cytotoxicity of NK and other immune cells via activating the TIGIT immune 
suppressor and invading immune system through targeting CEACAM1 to induce lymphocytic 
apoptosis 77,156. Moreover, F. nucleatum´s ability to interact with galactose lectin and endothelial 
cadherin expressed on various mammalian cell surfaces for adhesion and invasion via Fap2 and FadA 
proteins may explain its transmission ability and overrepresentation in distal organs 157–161. 
 
 
Fig. 6. No correlation between age and the circulating IgG plasma (A) or IgA salivary (B) antibody 





4.2.5  Salivary bacterial 16S DNA and antibody reactivities 
Targeted bacterial 16S DNA copy to F. nucleatum and G. adiacens determined by specific qPCR 
Taqman assays showed comparable gene copy levels between all groups. Universal 16S gene copy 
levels were comparable as well across the groups. Moreover, targeted and universal bacterial 16S DNA 
showed no correlations to the bacteria antibody reactivities.  
These findings bring many interesting questions whether mucosal secretory IgA antibodies in saliva 
has better specific immune recognition than plasma IgG to the virulent factor of oral commensals to 
create oral microbial symbiosis, or whether these translocated oral strains possess intrinsic feature able 
to mutate and hide their virulent factor to escape immune recognition when they disseminate to extra-
oral sites. A limitation of our study is that we targeted 16S DNA and antibodies to F. nucleatum at a 
species level, considering that the diversity of Fusobacterial community was reported to be significantly 
reduced when translocating from the oral cavity to gastric or colon sites, suggesting a selective 
translocation of Fusobacterial strains 162. However, the reported altered diversity of fusobacterial 
community between oral cavity and colon were found to be at the strain level rather than species or 
subspecies levels 163. Further studies to focus on the virulence factors of the transmissible strains are 
needed to understand their role in the transmission and exploit them for diagnostic and therapeutic 
purposes.  
 
4.3  Study III 
4.3.1  Salivary antibody responses to SARS-CoV-2 proteins 
A multiplexed bead-based immune array was used in this study. First, a panel of recombinant SARS-
CoV-2 viral proteins (n = 5) was tested to classify COVID-19 convalescence saliva samples (n = 74) 
from pre-pandemic saliva samples (n = 35). For salivary IgG, the absolute best accuracy was shown 
Fig. 7. Competitive ELISA with saliva samples pre-
incubated with or without Fap2 competitor, tested in F. 
nucleatum-coated wells. Statistical analysis was performed 




























with the spike trimers foldon (Spike-f, 88% sensitivity, 100% specificity) followed by the nucleocapsid 
C-terminus protein (NC-C, 66% sensitivity, 100% specificity). Of note, salivary IgA reactivities were 
weak in general in the convalescent samples, which were collected mainly 3-9 months after post-
symptoms-onset, and is consistent with previous studies reporting IgA antibody decay already 1 month 
post-symptoms-onset 164,165. In this study, a second cohort of undiagnosed individuals was invited to 
validate the utility of the salivary antibody assay. Here, the specific salivary antibody responses 
correlated significantly with recent Covid-19-like symptoms. Moreover, combining symptoms with 
other risk factors under past three months prior to sampling, such as 1) travel abroad; 2) contact with 
someone who has been confirmed to be infected with COVID-19; 3) clinical work, further increased 
IgG positivity frequency in this cohort (Figure 8A). This is not noted in those reporting no symptoms 




4.3.2  Salivary antibody tolerance to temperature and detergent pre-treatments 
The feasibility of using saliva in antibody testing was examined in a series of experimental simulations. 
Saliva inactivation by heat or detergent treatment for example at 56°C for 1 h or by 1% Triton X-100 
(Triton) showed a minor effect on antibody reactivity (the cut-off is based on 10 negative samples). In 
addition, storing samples at room temperature for one, two, or three days led to slight decay of antibody 
signals of positive samples.  
Unlike conventional ELISA, this study demonstrates that salivary antibodies to more than one antigen 
can be simultaneously detected by the bead-based multiplex array approach. Taken together, these 
results showed that the IgG specific to the SARS-CoV-2 spike full-length and nucleocapsid proteins in 
human saliva can be detected up to 9 months in mild COVID-19 cases by the bead-based array 
technology. This finding is in line with the SARS-CoV-2-specific IgG antibody duration in serum can 
be as long as up to 8 months after mild COVID-19, as reported recently in South Korea 166. However, 
further longitudinal study is warranted to rule out the possibility of reinfection.  Our data also showed 
that storing samples at room temperature has a minor effect on antibody reactivity, suggesting that a 
Fig. 8. Frequency of IgG 
positivity to spike trimer (Spike-f) 
or nucleocapsid (NC-C) in 
individuals with self-reported 
symptoms (A), or no symptoms 
(B) with additional risk factors 
such as traveling abroad, contact 
with COVID-19 diagnosed 





non-invasive antibody test approach with self-collection at home may serve as a complementary 
alternative to conventional blood serology testing. 
The limitations of our study are the relatively small size and the cross-sectional design. Unobtained 
biographical information of undiagnosed group (such as age and gender) limited sub-analysis options 
to evaluate antibody positivity based on these bio-parameters. Another limitation is the different 





5 CONCLUSIVE REMARKS 
Study I 
• Bacterial DNA and inflammation level in pancreas cysts correlate with the cystic neoplastic 
grade. 
• Pancreas microbiome of cyst fluid display co-occurrence and enrichment of oral bacterial 
species. 
• Bacteria DNA level in pancreas is associated to prior exposure to invasive endoscopic 
procedures. 
• Intracystic bacterial DNA testing of pancreas samples may have added values to guide the 
management of IPMN.  
• Reducing the pancreatic inflammatory microbiome may be a potential therapeutic strategy for 
IPMN patients. 
       
Study II 
• Elevated antibodies to oral pathogens (particularly F. nucleatum or Fap2 of F. nucleatum) in 
blood or salivary may reflect more severe form of IPMN. 
• Salivary IgA against oral pathogens holds promise as a non-invasive biomarker for early 
identification of high risk cystic tumors in the pancreas. 
 
Study III 
• Salivary antibody reactivity to SARS-CoV-2 spike and capsid antigens persist up to 9 months 
after mild COVID-19.  
• The virus-specific IgG in saliva appears stable and tolerates temperature and detergent pre-
treatments  
• A non-invasive saliva-based SARS-CoV-2 IgG test with home self-collection may serve as a 






6 POINTS OF PERSPECTIVE 
Study I 
The findings of the study warrant further studies to investigate the viability and oncogenic potential of 
the pancreatic microbiome in co-culture or in-vivo experimental models. Experimental studies to assess 
antibiotic treatment or other antimicrobial strategies as a therapeutic approach to reduce the risk of 
tumor progression are of great clinical importance. The link between invasive endoscopic procedures 
and pancreas bacteria contamination needs not only confirmatory studies but also calls for intervention 
studies, which is important in prevention of bacteria dissemination. 
Study II 
In order to investigate the role of oral bacteria in IPMN progression, metagenomic and metabolomic 
profile analysis of paired saliva and cyst fluid samples are an important area to study. In addition, 
exploring the role of these enriched oral microbiotas, particularly F. nucleatum, in the pancreatic tumor 
microenvironment worth further studies. Moreover, potential F. nucleatum modulation to cell-mediated 
immunity has not been examined in pancreatic tumor patients, which warrants further studies. 
Study III 
We investigated the persistence of binding antibodies to SARS-CoV-2 in a cross-sectional design. 
Longitudinal studies to investigate the kinetics of salivary immunity and antibody neutralization 
efficiency over time are awaited with great interest. Determining the correlation of antibody responses 
to protection, in natural infection as well as vaccination is highly important. Using saliva and multiplex 
strategy to monitor the COVID-19 vaccination programs should simplify the investigations vaccine 
immunity of any given environment. The magnitude and composition of salivary immunity required 
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